Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Continuous Bio-Manufacturing Skid Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The continuous bio-manufacturing skid market has seen rapid expansion in recent years. Its market size is anticipated to grow from $1.99 billion in 2025 to $2.26 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.6%. In the past, this growth was primarily due to increased biologics production volumes, an early shift from batch to continuous processing, the growing adoption of modular manufacturing concepts, the expansion of facilities for vaccine and enzyme production, and a heightened demand for flexible manufacturing setups.
The continuous bio-manufacturing skid market is projected for significant expansion in the coming years. Its value is set to reach $3.73 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.3%. This anticipated growth stems from factors such as the increasing implementation of fully continuous biologics production, greater investments in sophisticated bioprocess automation, a heightened need for rapid scale-up functionalities, the broadening of cell and gene therapy manufacturing, and an intensified emphasis on economical biologics production. Key trends expected during this period include a rise in the uptake of continuous and integrated bioprocessing skids, growing preference for modular and plug-and-play manufacturing systems, wider utilization of real-time process monitoring and control, the expansion of single-use continuous biomanufacturing platforms, and an elevated focus on process efficiency and throughput.
Get A Free Sample Report With In-Depth Market Insights:
Continuous Bio-Manufacturing Skid Market Growth Drivers: What’s Behind The Acceleration?
The anticipated expansion of the continuous bio-manufacturing skid market is linked to the growing need for biopharmaceuticals. Biopharmaceuticals are defined as medical products derived from biological origins, like proteins, nucleic acids, or live cells, utilized for disease treatment, prevention, or diagnosis. This heightened demand for biopharmaceuticals largely stems from the increasing incidence of chronic and genetic conditions, which necessitate advanced biologic treatments for proper care and control. Continuous bio-manufacturing skids improve biopharmaceutical output through efficient, automated, and scalable processes, boosting the effectiveness, uniformity, and pace of creating intricate therapies. For example, data from Cardinal Health Inc., a US-based healthcare company, revealed that by January 2023, the U.S. featured 40 FDA-approved biosimilar products, with 25 available on the market. This marks an increase from January 2022, when 33 FDA-approved biosimilars existed, with 21 commercially available. Consequently, the expanding need for biopharmaceuticals is fueling the growth within the continuous bio-manufacturing skid market.
Continuous Bio-Manufacturing Skid Market Segments: Where Is Growth Concentrated?
The continuous bio-manufacturing skid market covered in this report is segmented –
1) By Product Type: Single-Use Skids, Multi-Use Skids, Modular Skids
2) By Process: Upstream, Downstream, Integrated
3) By Application: Biopharmaceutical Production, Vaccine Manufacturing, Enzyme Production, Cell And Gene Therapy, Other Applications
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations, Research Institutes, Other End-Users
Subsegments:
1) By Single-Use Skids: Perfusion Bioreactor Skid, Tangential Flow Filtration Skid, Chromatography Skid, Buffer Preparation Skid
2) By Multi-Use Skids: Fed-Batch Bioreactor Skid, Downstream Purification Skid, Ultrafiltration Skid, Viral Inactivation Skid
3) By Modular Skid: Plug And Play Bioreactor Skid, Integrated Downstream Skid, Automated Sampling Skid, Real-Time Monitoring Skid
Continuous Bio-Manufacturing Skid Market Trends: What’s Defining The Industry’s Next Phase?
Leading firms within the continuous bio-manufacturing skid market are concentrating on creating novel solutions, including advanced biologics manufacturing platforms, aimed at improving efficiency, scalability, and the caliber of their products. These next-generation platforms represent sophisticated systems designed for fully integrated, uninterrupted production of biologics, featuring real-time oversight, greater efficiency, and uniform product quality. An example of this is the launch of EnzeneX 2.0, the subsequent iteration of its fully connected continuous manufacturing (FCCM) technology for biologics, by Enzene Biosciences Ltd., an India-based contract development and manufacturing organization, at CPHI Milan 2024 in October 2024. This patented system facilitates smooth, continuous processing from the perfusion stage to the final drug substance. Through the utilization of high-titer clones and optimized cell media, it boosts productivity, elevates target protein concentrations, and reduces variability between batches. Furthermore, the system integrates process analytical technology (PAT) to enable real-time monitoring and control, thereby guaranteeing consistent quality and operational effectiveness, alongside providing up to a 50% reduction in per-gram production costs. Ultimately, these platforms deliver scalable, economical biologics manufacturing capabilities that can be tailored to various modalities and media formulations.
Continuous Bio-Manufacturing Skid Market Key Participants And Competitive Landscape
Major companies operating in the continuous bio-manufacturing skid market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Garrett Industrial Systems Ltd., Sartorius AG, Getinge AB, ZETA GmbH, Pall Corporation, Repligen Corporation, ABEC Inc., Enzene Biosciences Limited, Pierre Guerin Technologies, Bioengineering AG, KeyPlants GmbH, G&G Technologies Pvt. Ltd., Scigenics Pvt. Ltd, Exentec B.V., PAK BioSolutions Inc., Stobbe Pharma GmbH, CPi Biotech Inc.
View The Full Continuous Bio-Manufacturing Skid Market Report:
Continuous Bio-Manufacturing Skid Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the continuous bio-manufacturing skid market in 2025. The regions covered in the continuous bio-manufacturing skid market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
